Uniquely Saving Lives

Plasma-derived therapies and their recombinant analogs, collectively referred to as plasma protein therapies, are unique, biologic medicines, versus synthetic or chemical medicines, because production begins with plasma, a biologic starting material. These unique therapies replace missing or deficient proteins found in plasma, allowing their recipients to lead healthier and more productive lives.

The patient populations that rely on plasma protein therapies generally require regular infusions or injections for the duration of their lives. Plasma protein therapies are not interchangeable and have been defined by regulators as sole-source biologic products because no generics or substitutions exist.